SUMMARY
LANOXIN (digoxin) is one of the cardiac (or digitalis) glycosides, a closely related group of drugs having in common specific effects on the myocardium. These drugs are found in a number of plants. Digoxin is extracted from the leaves of
Digitalis lanata. The term "digitalis" is used to designate the whole group of glycosides. The glycosides are composed of two portions: a sugar and a cardenolide (hence "glycosides").
Heart Failure: LANOXIN is indicated for the treatment of mild to moderate heart failure. LANOXIN increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by exercise capacity and heart failure-related hospitalizations and emergency care, while having no effect on mortality. Where possible, LANOXIN should be used with a diuretic and an angiotensin-converting enzyme inhibitor, but an optimal order for starting these three drugs cannot be specified.
Atrial Fibrillation: LANOXIN is indicated for the control of ventricular response rate in patients with chronic atrial fibrillation.
|
NEWS HIGHLIGHTS
Published Studies Related to Lanoxin Pediatric (Digoxin Pediatric)
Single daily dose of digoxin for maintenance therapy of infants and children with cardiac disease: is it reliable? [1994.09]
Between July 1990 and September 1991, 30 infants and children, most of whom had a congenital heart defect and who had been treated at least during the previous 20 days by two daily doses of digoxin and were in a stable clinical condition, were selected at random...
Successful treatment of propafenone, digoxin and warfarin overdosage with plasma exchange therapy and rifampicin. [2007]
We report here the successful treatment of a 16-year-old female who ingested 20 tablets of digoxin each containing 0.25 mg (total dose ingested equivalent to 0.1 mg/kg), 32 tablets of warfarin each containing 5mg (equivalent to 3.2 mg/kg), and approximately 15 tablets of propafenone each containing 300 mg (equivalent to 90 mg/kg)...
Application of two-point assay of digoxin serum concentration in studying population pharmacokinetics in Egyptian pediatric patients with heart failure: does it make sense? [2005.07]
Digoxin pharmacokinetics (PK) was studied among a selected group of Egyptian pediatric patients (n = 40) with an age range of 0.33 to 15 years. All the patients had heart failure and were maintained on i.v...
Digoxin toxicity: pediatric survival after asystolic arrest. [2005]
We report the first case of a child with known cardiac disease who presented in full cardiac arrest secondary to digoxin poisoning and was successfully resuscitated. A 12-week-old female presented 1-week status post surgical repair of a congenital heart anomaly in asystolic cardiac arrest... The patient was discharged 6 days after presentation with full neurological recovery.
Frequency of recurrence among infants with supraventricular tachycardia and comparison of recurrence rates among those with and without preexcitation and among those with and without response to digoxin and/or propranolol therapy. [2003.11.01]
Approximately 60% of children with supraventricular tachycardia (SVT) develop their initial episode by 1 year of age. Despite resolution in most of these patients by 1 year, approximately 30% of the SVT will recur... Furthermore, children with WPW syndrome who are refractory to treatment with digoxin and/or propranolol are at increased risk of SVT recurrence.
Clinical Trials Related to Lanoxin Pediatric (Digoxin Pediatric)
Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects [Not yet recruiting]
This study has been designed to confirm, in healthy subjects, the lack of a clinically
important pharmacokinetic interaction between Dimebon, at the proposed maximum commercial
dose of 20 mg TID (administered every 8 hours), and digoxin (Lanoxin®) 0. 125 mg QD, a
sensitive P-gp substrate recommended by FDA.
Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer [Recruiting]
This is a two part study looking at the effect of lapatinib on concentrations of digoxin in
the blood when both drugs are dosed together in Part 1; and looking at the safety and
antitumor effect of lapatinib when used together with possible additional anticancer therapy
as chosen at the doctor's discretion.
Drug Interaction Study - Effect of AZD5672 on the Pharmacokinetics of Digoxin [Recruiting]
Pharmacokinetic and Pharmacodynamic Interaction Study of Digoxin and Hawthorn [Completed]
Hawthorn (Crataegus oxyacantha) is a natural product that is popular in European and American
herbal medicine practice. Some of its cardiac uses include the treatment of high and low
blood pressure, rapid heart beat, chest pain, and blocked arteries. In many cases, it is
used as an adjuvant agent with other cardiac drugs such as digoxin, amiodarone, and warfarin.
To date, little information is known about the effect of hawthorn when taken with other
drugs and if toxicities occur when hawthorn is used with other drugs. The purpose of this
study is to examine the interaction between digoxin and hawthorn in eight healthy subjects.
Subjects will be recruited by advertisement. The design of the study will include a 10-day
and a three-week treatment phase of digoxin 0. 125 mg - 0. 25 mg/day and hawthorn (Crataegus
special extract WS1442, Schwabe Co.) 450 mg twice daily or placebo, with a randomized
crossover. There will be a three-week washout period in between treatment phases. On day 10
(phase I) and day 21 (phase II), subjects will have 12 blood samples drawn for
pharmacokinetic analysis. The plasma samples will be measured for digoxin concentration.
Additionally, the subjects will be assessed for any clinical toxicities or adverse events.
The significance of this study is to provide the clinician with information regarding the
safe use of digoxin in combination with the herbal supplement, hawthorn.
An Interaction Study With Digoxin and AZD1305 [Not yet recruiting]
The primary purpose of this study is to learn more about how digoxin is handled by the body,
i. e. absorption, distribution, metabolism and excretion, when administered alone and in
combination with AZD1305. Secondary purposes are to learn more about how AZD1305 is handled
by the body when administered alone and in combination with digoxin and to learn more about
how AZD1305 and digoxin administered alone and in combination affect the body.
|
